TY - JOUR
T1 - Association of CCL2, CCR2 and CCL5 genetic polymorphisms with the development and progression of benign prostatic hyperplasia
AU - Pang, Yangyang
AU - Li, Haoran
AU - Gong, Yuwen
AU - Jing, Suoshi
AU - Peng, Cheng
AU - Liu, Wei
AU - Zhao, Youli
AU - Wang, Hanzhang
AU - Kaushik, Dharam
AU - Rodriguez, Ronald
AU - Wang, Zhiping
N1 - Publisher Copyright:
© 2019 Spandidos Publications. All Rights Reserved.
PY - 2019/4
Y1 - 2019/4
N2 - Benign prostatic hyperplasia (BPH) is a common chronic disease in older males. The pathogenesis of BPH remains elusive but may be associated with chronic inflammation. Chemokines and chemokine receptors have been implicated as critical mediators in the immune response and inflammatory processes. In the present study, the aim was to evaluate the association of three polymorphisms in chemokine genes, namely C-C motif chemokine ligand (CCL)2 rs1024611, CC chemokine receptor 2 (CCR2) rs1799864 and CCL5 rs2107538, with BPH risk. These polymorphisms were genotyped in 109 patients with BPH and 160 control subjects, using the polymerase chain reaction and multiple ligase detection reaction method. The CCL5 rs2107538 polymorphism was identified to be associated with a significantly lower risk of BPH [A/G vs. G/G: Odds ratio (OR)=0.37, 95% confidence interval (CI)=0.17‑0.78; A/A+A/G vs. G/G: OR=0.39, 95% CI=0.19‑0.79; A vs. G: OR=0.58, 95% CI=0.35-0.96). However, this polymorphism was also associated with the development of larger prostate volumes in patients with BPH (A/G vs. G/G: OR=3.02, 95% CI=1.28‑7.11; AA + AG vs. GG: OR=2.83, 95% CI=1.28‑6.26; A vs. G: OR=1.94, 95% CI=1.08-3.49). The CCR2 rs1799864 polymorphism was associated with lower International Prostate Symptom Score values (A/A+A/G vs. G/G: OR=0.39, 95% CI=0.17‑0.91; A vs. G: OR=0.43, 95% CI=0.20‑0.90) and low Qmax (A/G vs. G/G: OR=0.38, 95% CI=0.16‑0.92; AA+AG vs. GG: OR=0.39, 95% CI=0.17-0.91) in the patients. No association was observed between the CCL2 rs1024611 polymorphism and BPH. These results suggest that the CCR2 and CCL5 genes may contribute to the occurrence and progression of BPH.
AB - Benign prostatic hyperplasia (BPH) is a common chronic disease in older males. The pathogenesis of BPH remains elusive but may be associated with chronic inflammation. Chemokines and chemokine receptors have been implicated as critical mediators in the immune response and inflammatory processes. In the present study, the aim was to evaluate the association of three polymorphisms in chemokine genes, namely C-C motif chemokine ligand (CCL)2 rs1024611, CC chemokine receptor 2 (CCR2) rs1799864 and CCL5 rs2107538, with BPH risk. These polymorphisms were genotyped in 109 patients with BPH and 160 control subjects, using the polymerase chain reaction and multiple ligase detection reaction method. The CCL5 rs2107538 polymorphism was identified to be associated with a significantly lower risk of BPH [A/G vs. G/G: Odds ratio (OR)=0.37, 95% confidence interval (CI)=0.17‑0.78; A/A+A/G vs. G/G: OR=0.39, 95% CI=0.19‑0.79; A vs. G: OR=0.58, 95% CI=0.35-0.96). However, this polymorphism was also associated with the development of larger prostate volumes in patients with BPH (A/G vs. G/G: OR=3.02, 95% CI=1.28‑7.11; AA + AG vs. GG: OR=2.83, 95% CI=1.28‑6.26; A vs. G: OR=1.94, 95% CI=1.08-3.49). The CCR2 rs1799864 polymorphism was associated with lower International Prostate Symptom Score values (A/A+A/G vs. G/G: OR=0.39, 95% CI=0.17‑0.91; A vs. G: OR=0.43, 95% CI=0.20‑0.90) and low Qmax (A/G vs. G/G: OR=0.38, 95% CI=0.16‑0.92; AA+AG vs. GG: OR=0.39, 95% CI=0.17-0.91) in the patients. No association was observed between the CCL2 rs1024611 polymorphism and BPH. These results suggest that the CCR2 and CCL5 genes may contribute to the occurrence and progression of BPH.
KW - Benign prostatic hyperplasia
KW - CCL2
KW - CCL5
KW - CCR2
KW - Polymorphism
UR - http://www.scopus.com/inward/record.url?scp=85062230187&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85062230187&partnerID=8YFLogxK
U2 - 10.3892/or.2019.7002
DO - 10.3892/or.2019.7002
M3 - Article
C2 - 30816510
AN - SCOPUS:85062230187
SN - 1021-335X
VL - 41
SP - 2491
EP - 2501
JO - Oncology reports
JF - Oncology reports
IS - 4
ER -